


not "narrowing" amendments; no limitations have been added
and none are intended.

Applicants respectfully await the results of a
first examination on the merits.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By

A handwritten signature in black ink, appearing to read 'S. Neimark', is written over a horizontal line.

Sheridan Neimark

Registration No. 20,520

SN:jaa

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

F:\,A\Aoyb\Kato18\PTO\2ndAmd Prelim Dec01.doc



RECEIVED

DEC 31 2001

TECH CENTER 1600/2900

Version with Markings to Show Changes Made

3. (Amended) The composition according to claim 1 ~~er 2~~, wherein the function of having an affinity for a virus is derived from a functional substance selected from the group consisting of anti-virus antibodies, heparin-II-binding domain of fibronectin, fibroblast growth factor, collagen and polylysine as well as functional equivalents thereof.

4. (Amended) The composition according to ~~any one of claims 1 to 3~~claim 1, wherein the function of having an affinity specific for a target cell is derived from a functional substance selected from the group consisting of proteins each having an affinity for the target cell, hormones, cytokines, anti-target cell antibodies, sugar chains, carbohydrates and cells.

5. (Amended) The composition according to ~~any one of claims 1 to 4~~claim 1, wherein the functional substance is a functional substance having an affinity specific for a target cell derived from a cell selected from the group consisting of vascular endothelial cells, inflammatory cells, hematopoietic stem cells, brain endothelial cells and bone marrow cells.

10. (Amended) The composition according to claim ~~8 or 9~~, wherein the functional substance having an affinity

for a virus is a functional substance selected from the group consisting of anti-virus antibodies, heparin-II-binding domain of fibronectin, fibroblast growth factor, collagen and polylysine as well as functional equivalents thereof.

11. (Amended) The composition according to ~~any one of claims 8 to 10~~ claim 8, wherein the functional substance having an affinity specific for a target cell is a functional substance selected from the group consisting of proteins each having an affinity for the target cell, hormones, cytokines, anti-target cell antibodies, sugar chains, carbohydrates and cells.

16. (Amended) The gene therapy method according to claim 14 ~~or 15~~, wherein the function of having an affinity for a virus is derived from a functional substance selected from the group consisting of anti-virus antibodies, heparin-II-binding domain of fibronectin, fibroblast growth factor, collagen and polylysine as well as functional equivalents thereof.

17. (Amended) The gene therapy method according to ~~any one of claims 14 to 16~~ claim 14, wherein the function of having an affinity specific for a target cell is derived from a functional substance selected from the group consisting of proteins each having an affinity for the target

cell, hormones, cytokines, anti-target cell antibodies, sugar chains, carbohydrates and cells.

18. (Amended) The gene therapy method according to ~~any one of claims 14 to 17~~claim 14, wherein the functional substance is a functional substance having an affinity specific for a target cell derived from a cell selected from the group consisting of vascular endothelial cells, inflammatory cells, hematopoietic stem cells, brain endothelial cells and bone marrow cells.

23. (Amended) The gene therapy method according to claim 21 ~~or 22~~, wherein the functional substance having an affinity for a virus is a functional substance selected from the group consisting of anti-virus antibodies, heparin-II-binding domain of fibronectin, fibroblast growth factor, collagen and polylysine as well as functional equivalents thereof.

24. (Amended) The gene therapy method according to ~~any one of claims 21 to 23~~claim 21, wherein the functional substance having an affinity specific for a target cell is a functional substance selected from the group consisting of proteins each having an affinity for the target cell, hormones, cytokines, anti-target cell antibodies, sugar chains, carbohydrates and cells.

40. (Amended) The composition, ~~the gene therapy method or the use~~ according to any one of claims 1 to 3926, wherein the target cell is a cell selected from the group consisting of hematopoietic stem cells, blood cells, leukocytes, lymphocytes, T cells, tumor-infiltrating lymphocytes, B cells and cancer cells.

42. (Amended) The composition, ~~the gene therapy method or the use~~ according to any one of claims 1 to 4126, wherein a protein encoded by the transferred gene is a therapeutic protein which is expressed upon expression of the gene in the target cell in an amount sufficient for the treatment.

43. (Amended) The composition, ~~the gene therapy method or the use~~ according to claim 42, wherein the protein is an enzyme or a cytokine.

44. (Amended) The composition, ~~the gene therapy method or the use~~ according to any one of claims 1 to 4326, wherein the virus is a virus vector.

45. (Amended) The composition, ~~the gene therapy method or the use~~ according to any one of claims 1 to 44claim 44, wherein the virus is a retrovirus vector, an adenovirus

vector, an adeno-associated virus vector or a vaccinia virus vector.